
Uflex Q2 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 4
Margin
Category 3
Fundraise
No
Order
N/A
Capex
Yes
1 of 4 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 4- UFlex aims to bridge the revenue gap, targeting to reduce the 15.5% H1 FY2024 revenue decline to a 10% decline for the full year.
- EBITDA margins are expected to improve to around 11.5% annually.
- Packaging films volumes rose 6.6% Q-o-Q, indicating growth momentum.
- Flexible packaging volumes increased 21% sequentially and 7% Y-o-Y, reflecting strong demand.
- Liquid packaging volumes are slightly up Y-o-Y by 0.2%.
- Q4 FY2024 is expected to see better volumes and margins, especially from aseptic packaging due to seasonality.
- Overseas markets like America are expected to improve further in Q3 and Q4, while Europe remains uncertain.
- India is showing robust volumes but margin pressure due to overcapacity.
- Capacity expansion projects (PET chips plant in India and Egypt, aseptic packaging debottlenecking) will enhance production by FY2024-end or early FY2025.
See what Uflex management said on margin guidance — free account, 30 seconds.
Fundraise plans
No- No explicit mention of new major fundraising through debt or equity in the near term.
- Current net debt stands at approximately Rs.4,750 Crores.
- Expected amortization payments around Rs.550 Crores annually will gradually reduce debt.
- Some additional debt may be raised for new plants, such as the PET chips plant under construction.
- Overall net debt expected to remain around Rs.5,000 Crores in the near future.
- No new major capacity expansions announced beyond the currently ongoing projects.
- From FY2026 onwards, debt is expected to reduce as there are no significant new expansions planned.
See what Uflex management said on order book — free account, 30 seconds.
Capex plans
Yes- Rs. 587 Crores capex for backward integration into pet chips plant at Panipat, India; commercial production expected by end of FY2024 or early FY2025.
- Pet chips plant commissioning planned in Egypt by end of FY2024 or slightly earlier.
- Aseptic packaging debottlenecking expected by September 2024, increasing capacity from 7 billion to 12 billion packs.
- No new major capacity expansion currently planned; focus on optimizing existing plants due to market uncertainties in Europe, America, and India.
- Some small capex possible for adding machines in value-added product lines but no new dedicated lines envisioned.
- PET expansion plants in India and Egypt are considered final expansion with no further expansion planned currently.
Track Uflex — get its next earnings analysis in your feed
How does Uflex rank vs peers in Industrial Products?
Pro featureHow does Uflex rank in Industrial Products?
Compare Uflex against every Industrial Products company (Q2 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Uflex's management said in earlier quarters
Others in Industrial Products this season
- KSB (Q2 FY27)
Revenue from operations (₹ Mn): . Key investor presentation takeaways from KSB Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
- Jindal Supreme (Q2 FY27)
For Q2 FY27, Revenue from Operations was ₹21,622 lakhs, a 36% year-on-year increase from ₹15,880 lakhs in Q2 FY26 (Page 6). Key investor presentation takeaways
- Supreme Engineering (Q2 FY27)
Revenue from operations for the quarter ended September 30, 2026: ₹578.74 lakh . Key results statement takeaways from Supreme Engineering Ltd's Q2 FY27 results
- Jindal Poly Film (Q2 FY27)
Year-on-Year Revenue Growth:** Approximately 26.5% increase [(73,806.55 . Key results statement takeaways from Jindal Poly Films Ltd's Q2 FY27 results statement